Looking forward to that increased News Flow Gary promoted at the July presentation.
I'm happy to sit and wait here , sometimes you just have to stand still and wait for the Money/ Demand to come to you..
I'll be here until the SNT 6302 Trial is completed ... every single factor surrounding SNT 6302 has been positive to date ,, me I would have it as the lead candidate to ramp up the SP as its a highly visual easily understood dermal treatment.
Dermal application being the lowest on the Complexity matrix well under Ingestion, Intravenous , Implant.
Burns and Scarring are highly visual with simple before and after shots,, Dr Fiona Woods doesn't make statements lightly not many topline PHD's + Surgeons rarely make statements at all.. Certainly when I hear words "Unprecedented Change"
“This exploratory clinical study has significantly enhanced our understanding of the role of LOX enzymes in scarring and the scar process itself. PXS-6302 safely inhibits these key enzymes to a significant degree and leads directly to an unprecedented change to the scar composition that we have not seen with any other form of treatment".
https://www.linkedin.com/posts/gary-phillips-838590_professor-fiona-wood-am-leading-pxs-6302-activity-6950678095397814272-Hm5S/
Chanel 9 News
Add to My Watchlist
What is My Watchlist?
